medicaid cover tirzepatide Medicare would costly weight loss drugs under Biden plan Medicare to Cover Blockbuster Obesity

Dose escalation up to 2 mg weekly may be considered if additional glycaemic control is required, following UK SmPC guidance

Bone Spine 88, 105091

Human trials are limited, long-term safety is unknown, and it has not been adopted in mainstream medicine

Canada is the only country where Novo Nordisk allowed the patent for its semaglutide drugs to expire, paving the way for regulatory exclusivity to end on Jan

Weight loss progress needs tracking

Rituximab (anti-CD20, depleting B cells) and Abatacept (CTLA-4-Ig, blocking T-cell co-stimulation) have shown modest, transient preservation of beta-cell function in recent-onset T1D patients